Investing.com -- JP Morgan upgraded Cinemark Holdings (NYSE:CNK) to “Overweight” from “Neutral” on growing confidence in the 2026-2027 film pipeline and reduced box office expectations for 2025 that now better align with the bank’s forecasts. JP Morgan also noted that market expectations have adjusted for potential share loss as theater capacity tightens, a dynamic it had previously flagged as a risk. On the positive side, visibility into future supply has improved meaningfully, particularly following updates from CinemaCon. Amazon (NASDAQ:AMZN) MGM’s commitment to produce 15 theatrical films annually by 2027 offers a replacement for lost 20th Century Fox output, which has weighed on the industry since Disney’s 2017 acquisition, the bank said. Channel checks with entertainment executives further support a healthy pipeline of upcoming projects. JP Morgan also pointed to Cinemark’s limited economic sensitivity, noting that theater attendance tends to correlate more with film quality than macroeconomic conditions. As an example, the firm cited Minecraft’s $162 million opening weekend, which came despite broader market volatility. While concerns remain around shortened theatrical windows and their effect on mid-budget films, the bank said it was encouraged by studios’ efforts to simplify and extend exclusivity periods. It set a December 2025 price target of $34, valuing the stock at the midpoint of a 6.5x–8.5x range and incorporating potential dilution or payout from convertibles. JP Morgan maintained a Neutral rating on IMAX (NYSE:IMAX) citing risks tied to China and exhibitor capital spending. Related articles Consumer Credit, Smucker Earnings, Yellen Speaks: 3 Things to Watch Coupa Software Tops Q1 EPS by 3c HealthEquity Tops Q1 EPS by 1c, Offers Guidance View Comments
JP Morgan upgrades Cinemark on improving 2026-27 film slate visibility
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...